{"id":"v920-consistency-lot-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5853519","moleculeType":null,"molecularWeight":"319.43"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"V920 is a recombinant zoster vaccine that uses non-live viral antigens to elicit cell-mediated and humoral immune responses against VZV. By boosting immunity to the virus that causes shingles, the vaccine aims to reduce the incidence and severity of herpes zoster and its complications, particularly in older adults and immunocompromised populations.","oneSentence":"V920 is a vaccine candidate designed to stimulate immune responses against varicella-zoster virus (VZV) to prevent herpes zoster and post-herpetic neuralgia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:01.663Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Prevention of post-herpetic neuralgia in adults aged 50 years and older"}]},"trialDetails":[{"nctId":"NCT02503202","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-17","conditions":"Prevention of Ebola Infection","enrollment":1197}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"V920 Consistency Lot A","genericName":"V920 Consistency Lot A","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"V920 is a vaccine candidate designed to stimulate immune responses against varicella-zoster virus (VZV) to prevent herpes zoster and post-herpetic neuralgia. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia in adults aged 50 years and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}